

PROLIGHT ANNOUNCES APPOINTMENT OF PROFESSOR MATT REED TO CLINICAL ADVISORY BOARD

Prolight Diagnostics announces today that Matt Reed, Professor of Emergency Medicine at Edinburgh University, will join the Clinical Advisory Board of the company. His appointment will bring additional insights into the implementation of point-of-care testing in the Emergency Department setting.

"We are delighted to welcome Professor Reed onto our Clinical Advisory Board. It is important that we gain the expertise of frontline clinicians to help us better understand the complex landscape of Emergency Department testing and Professor Reed's experience will be invaluable." said Ulf Bladin, CEO of Prolight Diagnostics.

In addition to his position at Edinburgh University, Professor Reed is a Consultant and NRS (NHS Research Scotland) Fellow at the Royal Infirmary of Edinburgh and Director of EMERGE (Emergency Medicine Research Group Edinburgh). Matt also chairs the UK RCEM (Royal College of Emergency Medicine) Research Committee.

His research focuses on challenging areas of cardiovascular acute care such as syncope, palpitations, and aortic dissection and the innovative use of novel technology including point-of-care biomarkers and ambulatory physiological monitoring. Matt has published more than 140 papers and has secured over £8.5 million in research funding.

"I'm delighted to join the Prolight Clinical Advisory Board and bring my expertise as an Emergency Department Clinician. Point-of-care testing has real potential to speed up decision-making, support earlier treatment, and improve both patient care and ED flow." said Professor Reed.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight announces appointment of Professor Matt Reed to Clinical Advisory Board